These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17548455)

  • 1. The 'never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples.
    Mannello F; Tonti GA; Canestrari F
    Mult Scler; 2007 Jun; 13(5):687-90. PubMed ID: 17548455
    [No Abstract]   [Full Text] [Related]  

  • 2. Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies.
    Fainardi E; Castellazzi M; Bellini T; Dallocchio F
    Mult Scler; 2007 May; 13(4):561-2. PubMed ID: 17463079
    [No Abstract]   [Full Text] [Related]  

  • 3. Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies.
    Fainardi E; Castellazzi M; Bellini T; Dallocchio F
    Mult Scler; 2007 Jun; 13(5):691-2. PubMed ID: 17615626
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation.
    Mannello F
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):611-4. PubMed ID: 18354094
    [No Abstract]   [Full Text] [Related]  

  • 5. Preanalytical biases in measurement of matrix metalloproteinases and their tissue inhibitors in peripheral blood.
    Jung K
    J Rheumatol; 2007 Apr; 34(4):890-2; author reply 892. PubMed ID: 17407248
    [No Abstract]   [Full Text] [Related]  

  • 6. Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data.
    Jung K
    Mult Scler; 2009 Nov; 15(11):1372-3; author reply 1374-5. PubMed ID: 19965559
    [No Abstract]   [Full Text] [Related]  

  • 7. Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results.
    Jung K
    J Infect Dis; 2008 Dec; 198(11):1722-3; author reply 1723-4. PubMed ID: 19000015
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
    Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity.
    Dietmann A; Helbok R; Lackner P; Issifou S; Lell B; Matsiegui PB; Reindl M; Schmutzhard E; Kremsner PG
    J Infect Dis; 2008 Jun; 197(11):1614-20. PubMed ID: 18700258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.
    Mannello F; Tanus-Santos JE; Meschiari CA; Tonti GA
    Anal Biochem; 2008 Mar; 374(1):56-63. PubMed ID: 18082127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling.
    Jung K
    Eur J Cardiothorac Surg; 2008 May; 33(5):944; author reply 945. PubMed ID: 18343680
    [No Abstract]   [Full Text] [Related]  

  • 12. Establishing reference values from adults: recommendation on procedures for the preparation of individuals, collection of blood, and handling and storage of specimens. Committee on Reference Values of the Scandinavian Society for Clinical Chemistry.
    Alström T; Gräsbeck R; Lindblad B; Solberg HE; Winkel P; Viinikka L
    Scand J Clin Lab Invest; 1993 Oct; 53(6):649-52. PubMed ID: 8266012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.
    Jung K; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2006 Nov; 373(1-2):180-1; author reply 182. PubMed ID: 16616058
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of blood sampling on circulating tissue inhibitors of metalloproteinases.
    Jung K
    Clin Cancer Res; 2006 Apr; 12(8):2648; author reply 2648-9. PubMed ID: 16638881
    [No Abstract]   [Full Text] [Related]  

  • 15. [Matrix metalloproteinases and their tissue inhibitors in children and young adults on chronic hemodialysis--preliminary results].
    Musiał K; Makulska I; Zwolńska D
    Pol Merkur Lekarski; 2009 Apr; 26(154):290-3. PubMed ID: 19580190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases.
    Mannello F
    Clin Chem; 2003 Feb; 49(2):339-40. PubMed ID: 12560371
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
    Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
    Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of technology in the pre-analytic phase].
    Hauwaert T
    Ann Biol Clin (Paris); 1998; 56(5):623. PubMed ID: 9793587
    [No Abstract]   [Full Text] [Related]  

  • 20. [Expression of bone morphogenetic proteins, matrix metalloproteinases and inhibitors of matrix metalloproteinases in lung cancers and their prognostic significance].
    Bieniasz M; Bartkowiak J; Szemraj J
    Postepy Biochem; 2008; 54(1):82-90. PubMed ID: 18610585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.